Telaprevir is an oral protease inhibitor (PI) for the treatment of hepatitis C virus (HCV) infection. HCV protease is a unique HCV enzyme that plays a key role in viral replication and may also help the virus evade host immune defenses.

Protease inhibitors;  Hepatitis C viruses use an essential enzyme called protease (pro-tee-aze) during their replication process. Certain drugs can interfere with this enzyme which stops the virus' ability to copy itself. ;

Polymerase inhibitors;  Each time hepatitis C viruses replicate, they use an enzyme called polymerase to copy their RNA (genetic code). Polymerase inhibitors are drugs that interfere with polymerase. 

2013
Incivek  (Telaprevir)

Archives
2012

Dec 2012
HCV Drug Incivek (telaprevir) - View Rash  Grade 1 and 2 
FDA   Drug Safety Communication/Data Summary: Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin

An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant Patients

INCIVEK® (telaprevir)-Updates label after reports of a ‘small number of fatal skin reactions’

Telaprevir & Boceprevir in Liver Transplantation 

Telaprevir therapy required tacrolimus dose reduction in liver transplant recipients with HCV

Telaprevir Post Liver Transplant  

Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: A 12-week pilot study providing safety and efficacy data 

HCV Response to IFN/ribavirin Hints at Response to Telaprevir

Nov
2012
Hepatitis C Responds Better to Triple Antiviral Therapy

Ontario doctors question long wait for hepatitis C drug Incivek

Sustained virologic response rates with telaprevir by response
after 4 weeks of lead-in therapy in patients with prior treatment
failure.

Hepatitis C in the DAA era during the current economic crisis:
Whom to treat? How to treat? When to  treat?

AASLD
AASLD-Telaprevir:Twice-Daily Telaprevir Achieved Viral Cure
(SVR12) Rates Similar to Those Treated Three Times Daily

Phase 2 Results Show Incivo (telaprevir), in Combination With Peginterferon Alfa and
Ribavirin, is Effective in Treating Patients Co-infected With Genotype-1 Chronic
Hepatitis C Virus and HIV

November
News
New agents for the treatment of hepatitis C – focus on telaprevir

Oct
2012
Triple Therapy for Hepatitis C: High Cure Rate, Greater Risks

Incivek (Telaprevir)-Hepatitis C Geno 2 Patient Treated

Treatment of experienced and naïve patients with hepatitis C: focus on telaprevir

Telaprevir, boceprevir offer similar efficacy for most patients with HCV 1

Telaprevir therapy required tacrolimus dose reduction in liver
transplant recipients with HCV

An  Open-Label Study of the Effect of Telaprevir in Combination
With Peginterferon  Alfa-2b and Ribavirin in Pediatric Subjects Infected With
HCV 

Sept
2012
Telaprevir-based triple therapy in liver transplanted HCV patients: A 12 week pilot study providing safety and  efficacy
Telaprevir: Added benefit in certain patients with hepatitis C 

Adding Telaprevir to HCV Regimen Worthwhile

Aug 2012
Telaprevir Triple Therapy:Lowering Ribavirin Dose Does Not Compromise SVR In HCV Patients

Telaprevir, Incivek &  sex

June 2012
Treating Hepatitis C Current Standard of Care and Emerging
Direct-acting Antiviral Agents

Worth the Wait?  Should chronic hepatitis C patients be treated
now or wait for promising therapies?

FDA  Hepatitis Update - Incivek (telaprevir) product labeling
revised

Drug  Interactions - Telaprevir and buprenorphine.

USE OF TELAPREVIR PLUS PEG INTERFERON/RIBAVIRIN FOR NULL RESPONDERS POST OLT WITH
ADVANCED FIBROSIS/CHOLESTATIC HEPATITIS C

Quality of Life Undiminished by Telaprevir in Chronic Hepatitis C

One Year Post-Launch, The Protease Inhibitors, Incivek and Victrelis

May
2012
Vertex warned over misleading hep C drug promotion

April
2012
NICE has given its final recommendation for two new hepatitis C pills in an expedited review.
INCIVEK™ (telaprevir) Now Funded for People With Hepatitis C in Quebec and Saskatchewan
Telaprevir May Cause Severe Cutaneous Eruptions NEW YORK  (Reuters Health)
Vertex Update-Plans enrollment for Phase 2b study all-oral (interferon-free) treatment regimen
EASL-INCIVO® (Telaprevir) SVR Rates Unaffected by Ribavirin Dose
Reduction in Treatment Naïve and Previously Treated Patients With Genotype-1
Chronic HCV

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and
Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials

High Cost of Telaprevir Overshadows Clinical Benefits in Patient
Subset

March
2012
NICE publishes final draft guidance on telaprevir for chronic hepatitis C
Healthcare guidance body NICE has today (16 March)
issued final  draft guidance recommending telaprevir (Incivo, Janssen Cilag), in combination with  
peginterferon alfa and ribavirin, as an option for the treatment of   genotype 1
chronic hepatitis C in adults with compensated liver disease [1].

NCIVEK interim results:74% People Co-Infected with Hepatitis
C/HIV Had Undetectable Hepatitis C Virus 12 Wks After TX Ended
(SVR12)
Data showed 74 percent (28/38) of patients who were
treated with INCIVEK (in-SEE-veck) combination therapy had undetectable
hepatitis C virus (HCV RNA) 12 weeks after the end of all study treatment
(SVR12) compared to 45 percent (10/22) who were treated with
pegylated-interferon and ribavirin alone.

Feb 2012
Vertex Announces 12-Week On-Treatment Data and SVR4 From Phase 2 Study of
Interferon-Free (All-Oral) Treatment Regimen of INCIVEK®, VX-222 and Ribavirin
in People with Genotype 1 Hepatitis C

Jan 2012
All About; Incivek (Telaprevir)-An Oral Protease Inhibitor for  Hepatitis C Virus
Infection

2011
Dec
2011
Incivek and Victrelis Usage as Part of Triple Therapy Hepatitis C Regimen is Emerging as the New Standard of Care for Genotype 1 Patients
Watch-The Coming of Age of Direct Anti-Viral Agents for HCV